0001415889-24-022361.txt : 20240827 0001415889-24-022361.hdr.sgml : 20240827 20240827194447 ACCESSION NUMBER: 0001415889-24-022361 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240827 FILED AS OF DATE: 20240827 DATE AS OF CHANGE: 20240827 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leheny A. Rachel CENTRAL INDEX KEY: 0001484729 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39538 FILM NUMBER: 241250651 MAIL ADDRESS: STREET 1: C/O ANTHERA PHARMACEUTICALS, INC. STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CalciMedica, Inc. CENTRAL INDEX KEY: 0001534133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452120079 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-952-5500 MAIL ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: CalciMedica, Inc. /DE/ DATE OF NAME CHANGE: 20230322 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG VISION, INC. DATE OF NAME CHANGE: 20170717 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG, Inc. DATE OF NAME CHANGE: 20150303 4 1 form4-08272024_110843.xml X0508 4 2024-08-27 0001534133 CalciMedica, Inc. CALC 0001484729 Leheny A. Rachel C/O CALCIMEDICA, INC. 505 COAST BLVD. S. #307 LA JOLLA CA 92037 true true true false CHIEF EXECUTIVE OFFICER 0 Common Stock 2024-08-27 4 P 0 1000 4.1898 A 110926 D Common Stock 1000 I By Spouse Common Stock 356989 I By Valence Investments SPV IV, LLC Common Stock 66228 I By Valence Investments SPV V, LLC Common Stock 316109 I By Valence Investments SPV VI, LLC The weighted average purchase price for the transaction reported was $4.1898, and the range of prices were between $4.20 and $4.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. /s/ John Dunn, Attorney-in-Fact 2024-08-27